Not a good buy right now: the stock is in a broader downtrend (bearish moving averages) while fundamentals deteriorated sharply in the latest quarter.
With no Intellectia buy signals today and no near-term catalysts, the risk/reward is unfavorable for an impatient buyer.
Best stance here is to avoid/new buyers stay out; existing holders should consider exiting into any bounce toward resistance (around $2.47).
Technical Analysis
Trend: Bearish (SMA_200 > SMA_20 > SMA_5), indicating the primary trend is still down.
Momentum: MACD histogram slightly positive and expanding (0.0034) suggests a potential short-term bounce, but it’s counter-trend.
RSI: 43.28 (neutral) — not oversold, so there’s no strong mean-reversion “forced bounce” signal.
Key levels: Price ~$2.18 is below the pivot (2.287).
Support: 2.103 (S1), then 1.99 (S2)
Resistance: 2.47 (R1), then 2.583 (R2)
Pattern-based outlook (provided): modest upside bias over 1 month (+3.57%) but flat-to-negative near-term; not compelling given the dominant downtrend.
Longer-term upside scenario (per analysts who remain constructive): if Medicare Advantage market stabilizes and carrier relationships normalize, revenue/margins could recover.
Neutral/Negative Catalysts
Severe business deterioration in the latest reported quarter (major revenue decline and deeply negative profitability).
Carrier relationship disruption: at least one large carrier suspended its relationship (per RBC commentary), creating real near-term topline risk.
Analyst sentiment deteriorating: downgrades and sharp price target cuts suggest Street confidence weakened.
No supportive near-term news flow/catalyst in the last week; difficult to justify urgency for entry.
Congress/politician activity: No recent congress trading data available (no confidence signal from that channel).
Financial Performance
Latest quarter: 2025/Q3.
Revenue: 34.19M, down -71.10% YoY (sharp contraction).
Net income: -166.84M, down -2950.91% YoY (loss ballooned materially).
Overall: financial trend is strongly negative, which overwhelms the small short-term technical improvement (MACD).
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent trend: multiple negative revisions.
2025-11-18: William Blair downgraded to Market Perform from Outperform; cited market headwinds likely through 2026, cash-flow uncertainty, and limited diversification progress.
2025-11-26: RBC Capital cut price target to $5 from $12; maintained Sector Perform; noted Q3 significantly below expectations due to topline weakness tied to a large carrier suspension.
2025-11-14: Noble Capital kept Outperform but cut price target to $10 from $20; expects challenging environment to last several quarters.
Wall Street pros vs cons:
Pros: some belief in longer-term recovery once Medicare Advantage stabilizes (Noble still Outperform).
Cons: near-to-mid-term fundamentals and industry dynamics are pressured; multiple firms signaling limited visibility and reduced confidence via downgrades/target cuts.
Net read: Street stance skewed cautious/defensive right now, which does not support an “impatient buy now” approach.
People Also Watch
Wall Street analysts forecast GOCO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GOCO is 7.5 USD with a low forecast of 5 USD and a high forecast of 10 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast GOCO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GOCO is 7.5 USD with a low forecast of 5 USD and a high forecast of 10 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 1.950
Low
5
Averages
7.5
High
10
Current: 1.950
Low
5
Averages
7.5
High
10
RBC Capital
Sector Perform
downgrade
$12 -> $5
AI Analysis
2025-11-26
Reason
RBC Capital
Price Target
$12 -> $5
AI Analysis
2025-11-26
downgrade
Sector Perform
Reason
RBC Capital lowered the firm's price target on GoHealth to $5 from $12 and keeps a Sector Perform rating on the shares. The firm is updating its model following the company's Q3 results, which came in significantly below expectations due to topline weakness as a result of one large carrier suspending its relationship with, the analyst tells investors in a research note.
William Blair
Outperform -> Market Perform
downgrade
2025-11-18
Reason
William Blair
Price Target
2025-11-18
downgrade
Outperform -> Market Perform
Reason
William Blair downgraded GoHealth to Market Perform from Outperform.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GOCO
